ACM
AVIR icon

ADAR1 Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

ADAR1 Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-110,000
Closed -$369K – 215
2024
Q4 		$369K Buy
+110,000
New +$366K 0.07% 126

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ADAR1 Capital Management's AVIR Position: Q1 2025 in Review

ADAR1 Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2025, closing a stake of 110,000 shares — an estimated $369K sold.

ADAR1 Capital Management first reported a position in AVIR in Q4 2024 and held it in 1 quarter. The position peaked at $369K in Q4 2024. 103 funds tracked by Wall St. Rank hold AVIR as of Q1 2025.

  • ADAR1 Capital Management reported no remaining Atea Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 110,000 Atea Pharmaceuticals shares in Q1 2025, an estimated $369K.
  • ADAR1 Capital Management first reported a position in Atea Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • ADAR1 Capital Management's Atea Pharmaceuticals position peaked at $369K in Q4 2024.
  • 103 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2025.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.